Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
1.680
-0.040 (-2.33%)
Oct 14, 2024, 4:00 PM EDT - Market closed

Company Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.

The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.

The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.

It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid.

Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Ltd.
Compugen logo
Country Israel
Founded 1993
IPO Date Aug 11, 2000
Industry Biotechnology
Sector Healthcare
Employees 68
CEO Anat Cohen-Dayag

Contact Details

Address:
Azrieli Center, Building D
Holon, 5885849
Israel
Phone 972 3 765 8585
Website cgen.com

Stock Details

Ticker Symbol CGEN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001119774
CUSIP Number M25722105
ISIN Number IL0010852080
SIC Code 2836

Key Executives

Name Position
Dr. Anat Cohen-Dayag Ph.D. Chief Executive Officer, President and Director
Dr. Eran Ophir Ph.D. Chief Scientific Officer
Dr. Zurit Levine Ph.D. Senior Vice President of Technology Innovation
Dr. Pierre Ferre Ph.D. Vice President of Preclinical Development
David Silberman CPA Chief Financial Officer
Yvonne Naughton Head of Investor Relations and Corporate Communications
Eran Ben Dor General Counsel and Corporate Secretary
Dorit Amitay Vice President of Human Resources
Dr. Yaron Turpaz M.B.A., Ph.D. Senior Vice President and Senior Advisor of Data and Informatics Solutions
Rivka Schwartz Vice President Research and Discovery

Latest SEC Filings

Date Type Title
Sep 13, 2024 6-K Report of foreign issuer
Aug 6, 2024 6-K Report of foreign issuer
Aug 5, 2024 6-K Report of foreign issuer
Jul 29, 2024 6-K Report of foreign issuer
May 30, 2024 6-K Report of foreign issuer
May 20, 2024 6-K Report of foreign issuer
May 15, 2024 6-K Report of foreign issuer
Mar 5, 2024 20-F Annual and transition report of foreign private issuers
Mar 5, 2024 6-K Report of foreign issuer
Feb 15, 2024 6-K Report of foreign issuer